Skip to main content Accessibility help
×
Home

Information:

  • Access
  • Cited by 4

Actions:

      • Send article to Kindle

        To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

        Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

        Find out more about the Kindle Personal Document Service.

        Withdrawing interferon-α from psychiatric patients: clinical care or unjustifiable stigma?
        Available formats
        ×

        Send article to Dropbox

        To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

        Withdrawing interferon-α from psychiatric patients: clinical care or unjustifiable stigma?
        Available formats
        ×

        Send article to Google Drive

        To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

        Withdrawing interferon-α from psychiatric patients: clinical care or unjustifiable stigma?
        Available formats
        ×
Export citation

Abstract

IFN-α is an effective therapy for chronic viral hepatitis C and today still represents an effective first-line treatment. Unfortunately, its use is associated with a number of side-effects, including psychiatric problems like depression, mania, psychosis, delirium and other cognitive disturbances. Clinicians have been concerned about the risks of worsening of pre-existent psychiatric disorders and of precipitating suicidal attempts in psychiatric patients. The presence of a mental illness is, therefore, often deemed to be a contraindication to the use of antiviral treatment. However, this amounts to stigmatization and discrimination, as it basically implies withholding a life-saving medical treatment because of a psychiatric diagnosis. Is this clinically and socially acceptable? With novel treatments now entering clinical practice as adjuvant to IFN-α, it is particularly important to make a statement now, to ensure that psychiatric patients are not left behind. The aim of this editorial is to critically discuss this notion, by reviewing the few studies (n = 14) that have indeed administered IFN-α to patients with a pre-existing psychiatric disorder. We find evidence that these patients have rates of treatment adherence and sustained virological response similar to those of non-psychiatric patients, and that their IFN-α-induced psychiatric symptoms respond successfully to clinical management. We conclude that there is no support to withdrawing IFN-α therapy from psychiatric patients.

Introduction

Hepatitis C virus (HCV) infection is a major health problem affecting approximately 170 million people worldwide and 4 million of people in the USA (Asnis & De La Garza, 2006). Up to 85% of HCV-infected individuals may develop chronic hepatitis C, a disease associated with serious clinical complications, including cirrhosis of the liver and hepatocellular carcinoma. Chronic hepatitis C is the leading cause of liver transplantation in the developed world. It is estimated that there are approximately 5 million carriers of HCV in Europe, 70–80% of whom are likely to develop a chronic infection. In the UK, around 216 000 individuals are chronically infected with hepatitis C; and, as in all countries, the major risk factor for infection is injecting drug use (HPA, 2011). Therefore, it is easy to understand the importance of using appropriate antiviral treatments to successfully induce a viral remission, in order to reduce the morbidity and mortality associated with chronic hepatitis C.

First-line treatment consists of a combination therapy with pegylated IFN-α (pegIFN-α) plus ribavirin. In pegIFN-α, polyethylene glycol is added to make IFN-α's half-life longer, thus allowing once-weekly administration. This combination therapy can reach a sustained viral eradication in 45–95% of patients, according to viral genotype, viral load and treatment adherence. Novel protease inhibitor antiviral drugs will soon enter clinical care, and promise to increase considerably the rate of viral eradication; but they will be added to IFN-α – not be a substitute for it.

IFN-α neuropsychiatric side-effects

Unfortunately, the use of IFN-α is associated with numerous side-effects, both medical and neuropsychiatric. Among the first, there are flu-like symptoms, including fever, chills, malaise, tachycardia, headache, arthralgias and myalgias, occurring in more than 30% of patients, usually at the beginning of the therapy. Neuropsychiatric side-effects are also common, and there are reports of a variety of symptoms, including depressive syndromes, manic and psychotic episodes, and delirium. In a previous review (Quelhas & Lopes, 2009), prospective studies (that excluded patients with a lifetime history of psychiatric disorders) report an incidence of IFN-α-induced neuropsychiatric symptoms of 12–41%, while studies without this exclusion criterion report an incidence of 17–58%. Depression appears to be the most common side-effect in patients with chronic hepatitis C, and the incidence of major depressive episodes (MDEs), diagnosed according to DSM-IV-TR criteria, generally ranges from 12% to 42% (Quelhas & Lopes, 2009). The incidence of mania during IFN-α treatment is unknown; however, several cases have been reported, including cases of mania emerging spontaneously after IFN-α-induced depression and/or after withdrawal of IFN-α, and reports of ‘switches’ from depression to mania during antidepressant therapy (Quelhas & Lopes, 2009). Cognitive side-effects, especially memory disturbances and concentration problems, have also been found in 10–20% of patients receiving IFN-α, with the risk of cognitive decline possibly being higher with a larger cumulative dose of IFN-α and a longer duration of treatment. There are a few case reports of psychotic episodes induced by IFN-α therapy (Quelhas & Lopes, 2009).

Worsening of psychiatric symptoms in IFN-α therapy

Generally, patients with chronic hepatitis C tend to have a significant history of psychopathology (Yovtcheva et al. 2001), which has been considered by some authors as a significant cause for treatment withdrawal, due to the theoretical risk of worsening of psychiatric symptomatology induced by IFN-α treatment. In particular, concerns have been raised about worsening or exacerbation of depression or of suicidal ideation, as well as of psychotic symptoms in patients suffering from bipolar disorder and psychotic illnesses. As recently as in the 2012 Recommendations from the USA National Hepatitis C Program Office, it is prescribed that ‘uncontrolled depression or active suicidal ideation is an absolute contraindication to IFN-based therapies’ (Yee et al. 2012). While we agree with the accepted clinical practice that patients with active psychopathology should be assessed and supported before starting IFN-α, the wording of the recommendation undoubtedly confirms the degree of anxiety by which medical professionals see psychiatric patients in this context. As we have argued already 10 years ago (Pariante et al. 2002), withholding IFN-α inappropriately, especially from members of a stigmatized class, raises questions about fairness and discrimination.

The evidence

The aim of this editorial is to discuss the existing literature with regard to the administration of IFN-α therapy in patients with chronic hepatitis C and a current psychiatric illness. Studies were identified by using the PubMed database, cross-searching for ‘Interferon-α’, ‘psychiatric symptoms’ and ‘chronic hepatitis C’. Further references were obtained from bibliographies of the reviewed articles. Fourteen studies were considered eligible, and are summarized in Table 1, with details of the findings. Overall, most studies did not find a significantly higher risk of IFN-α-induced neuropsychiatric toxicity in patients with a psychiatric diagnosis, once the higher baseline psychopathology was taken into account. Interestingly, patients with severe mental illnesses, such as schizophrenia, seem also to be resilient during IFN-α. Furthermore, no higher suicidal risk was recorded in these patients. Of particular relevance, and consistently across all studies, is the fact that the rates of completion of therapy and sustained virological response are comparable between psychiatric and non-psychiatric patients.

Table 1. Summary of studies on psychiatric patients taking interferon-α

CESD, Center for Epidemiologic Studies Depression Scale; IFN, interferon; PHQ, Physician Health Questionnaire; PTSD, post-traumatic stress disorder; MDQ, Mood Disorders Questionnaire; MU, million units.

Conclusions

Our analysis of the relatively scant literature highlights that patients with a psychiatric illness have rates of treatment adherence and sustained virological response similar to those of non-psychiatric patients. Moreover, the majority of the studies do not show a significantly higher neurotoxicity of IFN-α therapy in these patients; and even in those studies that find a greater incidence of psychiatric adverse events, psychiatric patients are able to successfully complete the therapy. The lack of an increased risk of suicide in psychiatric patients is also consistent with a recent review on this topic (Sockalingam et al. 2011), which also found that the evidence for an increased suicide risk during IFN-α is largely anecdotal. In most cases, a combination of psychotropic and psychosocial interventions can be used to both prevent worsening of existing symptoms and to manage patients who show a reactivation of psychiatric problems. In fact, there is reasonably good evidence in favour of use of antidepressants, for both prophylaxis and treatment of anxiety and depressive symptoms induced by IFN-α (Baraldi et al. 2012). In addition, the early involvement of a multidisciplinary therapeutic approach, such as the assessment and follow-up with liaison psychiatrists and psychologists (Neri et al. 2010), or an interdisciplinary nurse-managed treatment programme, can be used to support patients with pre-existent psychiatric problems undergoing IFN-α therapy (Gardenier et al. 2011). It should be noted that it is important not to underestimate the fact that patients with no psychiatric history have virtually the same risk of developing IFN-α-induced side-effects, and as such they may suffer even more from the lack of management programmes and prophylactic strategies. In summary, while we support the notion of assertive psychosocial and pharmacological prevention in these patients, we find no evidence that patients with a pre-existing psychiatric disorder should not be treated with interferon-α; and withdrawal of such treatment should be considered as discrimination.

Acknowledgements

This paper received funding from The NIHR ‘Biomedical Research Centre for Mental Health’, Institute of Psychiatry and South London and Maudsley NHS Foundation Trust and the Commission of European Communities 7th Framework Programme Collaborative Project Grant Agreement no. 22963 (Mood Inflame).

DECLARATION OF INTEREST

None.

References

Asnis, GM, De La Garza, R (2006). Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology and treatment approaches. Journal of Clinical Gastroenterology 40, 322335.
Baraldi, S, Hepgul, N, Mondelli, V, Pariante, CM (2012). Symptomatic treatment of interferon-α-induced depression in hepatitis C: a systematic review. Journal of Clinical Psychopharmacology 32, 531543.
Dieperink, E, Ho, SB, Thuras, P, Willenbring, ML (2003). A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 44, 104112.
Dieperink, E, Leskela, J, Dieperink, ME, Evans, B, Thuras, P, Ho, SB (2008). The effect of pegylated interferon-alpha2b and ribavirin on posttraumatic stress disorder symptoms. Psychosomatics 49, 225229.
Evon, DM, Ramcharran, D, Belle, SH, Terrault, NA, Fontana, RJ, Fried, MW (2009). Virahep-C Study Group. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. American Journal of Gastroenterology 104, 29492958.
Gardenier, D, Wisnivesky, J, McGinn, LK, Kronish, IM, McGinn, TG (2011). Hepatitis C treatment completion in individuals with psychiatric comorbidity and depression. Gastroenterology Nursing 34, 102106.
Ho, SB, Nguyen, H, Tetrick, LL, Opitz, GA, Basara, ML, Dieperink, E (2001). Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. American Journal of Gastroenterology 96, 157164.
HPA (2011). Hepatitis C in the UK, Report. Health Protection Agency, London.
Huckans, M, Mitchell, A, Ruimy, S, Loftis, J, Hauser, P (2010). Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophrenia Bulletin 36, 165172.
Lang, JP, Melin, P, Ouzan, D, Rotily, M, Fontanges, T, Marcellin, P, Chousterman, M, Cacoub, P; CheObs Study Group (2010). Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study. Antiviral Therapy 15, 599606.
Lim, C, Olson, J, Zaman, A, Phelps, J, Ingram, KD (2010). Prevalence and impact of manic traits in depressed patients initiating interferon therapy for chronic hepatitis C infection. Journal of Clinical Gastroenterology 44, 141146.
Mulder, RT, Ang, M, Chapman, B, Ross, A, Stevens, IF, Edgar, C (2000). Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. Journal of Gastroenterology and Hepatology 15, 300303.
Neri, S, Bertino, G, Petralia, A, Giancarlo, C, Rizzotto, A, Calvagno, GS, Mauceri, B, Abate, G, Boemi, P, Di Pino, A, Ignaccolo, L, Vadala', G, Misseri, M, Maiorca, D, Mastrosimone, G, Judica, A, Palermo, F (2010). A multidisciplinary therapeutic approach for reducing the risk of psychiatric side-effects in patients with chronic hepatitis C treated with pegylated Interferon alpha and ribavirin. Journal of Clinical Gastroenterology 44, 210217.
Pariante, CM, Landau, S, Carpiniello, B; Cagliari Group (2002). Interferon alpha-induced adverse effects in patients with a psychiatric diagnosis. New England Journal of Medicine 347, 148149.
Pariante, CM, Orrù, MG, Baita, A, Farci, MG, Carpiniello, B (1999). Treatment with interferon alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 354, 131132.
Quelhas, R, Lopes, A (2009). Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. Journal of Psychiatric Practice 15, 262281.
Schaefer, M, Hinzpeter, A, Mohmand, A, Janssen, G, Pich, M, Schwaiger, M, Sarkar, R, Friebe, A, Heinz, A, Kluschke, M, Ziemer, M, Gutsche, J, Weich, V, Halangk, J, Berg, T (2007). Hepatitis C treatment in ‘difficult-to-treat’ psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 46, 991998.
Schaefer, M, Schmidt, F, Folwaczny, C, Lorenz, R, Martin, G, Schindlbeck, N, Heldwein, W, Soyka, M, Grunze, H, Koenig, A, Loeschke, K (2003). Adherence and mental side-effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology 37, 443451.
Schaefer, M, Schwaiger, M, Garkisch, AS, Pich, M, Hinzpeter, A, Uebelhack, R, Heinz, A, van Boemmel, F, Berg, T (2005). Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. Journal of Hepatology 42, 793798.
Sockalingam, S, Links, PS, Abbey, SE (2011). Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. Journal of Viral Hepatitis 18, 153160.
Van Thiel, DH, Friedlander, L, Molloy, PJ, Fagiuoli, S, Kania, RJ, Caraceni, P (1995). Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. European Journal of Gastroenterology and Hepatology 7, 165168.
Yee, HS, Chang, MF, Pocha, C, Lim, J, Ross, D, Morgan, TR, Monto, A; Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Office (2012). Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. American Journal of Gastroenterology 107, 669689.
Yovtcheva, SP, Rifai, MA, Moles, JK, Van Der Linden, BJ (2001). Psychiatric comorbidity among hepatitis-C-positive patients. Psychosomatics 42, 411415.